Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
Ilaria Alborelli, Katharina Leonards, Sacha I. Rothschild, et al.
The Journal of Pathology (2019) Vol. 250, Iss. 1, pp. 19-29
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette M. Sholl, Fred R. Hirsch, David Hwang, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 9, pp. 1409-1424
Open Access | Times Cited: 238
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Diana Merino Vega, Laura M. Yee, Lisa M. McShane, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1626-1636
Open Access | Times Cited: 132
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 8, pp. 2139-2147
Open Access | Times Cited: 111
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
Antonio Galvano, Valerio Gristina, Umberto Malapelle, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100124-100124
Open Access | Times Cited: 105
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Seong‐Keun Yoo, Conall Fitzgerald, Byuri Angela Cho, et al.
Nature Medicine (2025)
Open Access | Times Cited: 6
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic
Seminars in Cancer Biology (2021) Vol. 79, pp. 4-17
Closed Access | Times Cited: 97
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
Albrecht Stenzinger, Volker Endris, Jan Budczies, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 7, pp. 1177-1189
Open Access | Times Cited: 96
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
Anastasia Mpakali, Efstratios Stratikos
Cancers (2021) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 90
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis
Hongsheng Deng, Yi Zhao, Xiuyu Cai, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 170, pp. 103582-103582
Closed Access | Times Cited: 66
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Jingjing Qu, Quanhui Mei, Li Liu, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 62
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Hironori Uruga, Mari Mino‐Kenudson
Virchows Archiv (2021) Vol. 478, Iss. 1, pp. 31-44
Closed Access | Times Cited: 59
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Yue Pan, Yucheng Fu, Yue Zeng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 45
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Suna Zhou, Haihua Yang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 33
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects
Wanting Hou, Yaqin Zhao, Hong Zhu
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15321-15321
Open Access | Times Cited: 23
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Rui Li, Dongsheng Han, Jiping Shi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188420-188420
Closed Access | Times Cited: 51
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab
Bo Wei, John Kang, Miho Kibukawa, et al.
Journal of Molecular Diagnostics (2022) Vol. 24, Iss. 6, pp. 600-608
Open Access | Times Cited: 38
The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
Jinlong Cao, Xin Yang, Siyu Chen, et al.
Translational Oncology (2022) Vol. 20, pp. 101375-101375
Open Access | Times Cited: 33
New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis
Shuichi Shinohara, Yusuke Takahashi, Hiroyasu Komuro, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e003765-e003765
Open Access | Times Cited: 29
Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
Leonie I. Kroeze, Richarda M. de Voer, Eveline J. Kamping, et al.
Journal of Molecular Diagnostics (2020) Vol. 22, Iss. 6, pp. 757-769
Open Access | Times Cited: 49
Biomarkers for immunotherapy for treatment of glioblastoma
John Lynes, Anthony Nwankwo, Hannah Sur, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000348-e000348
Open Access | Times Cited: 49
Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Taobi Huang, Xia Chen, Huiyun Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 37
Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
Stanislav Fridland, Jaeyoun Choi, Myungwoo Nam, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002551-e002551
Open Access | Times Cited: 33
Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
Shixin Ma, He Nie, Chaoyu Wei, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status
Walid Shalata, Natalie Maimon Rabinovich, Abed Agbarya, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1825-1825
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top